Breaking News Instant updates and real-time market news.

SHPG

Shire

$162.52

(0.00%)

, TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

09:39
04/19/18
04/19
09:39
04/19/18
09:39

Shire has 'at least one or two other' interested bidders, CNBC says

After Shire (SHPG) confirmed that it has received, and rejected, three conditional proposals from Takeda (TKPYY) regarding a possible offer for the company, CNBC's David Faber reported on air that his sources indicate that there are "at least one or two" other companies interested in bidding for Shire. Those others prefer to have a quiet dialogue with Shire, according to Faber.

SHPG

Shire

$162.52

(0.00%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

  • 21

    Dec

SHPG Shire
$162.52

(0.00%)

02/22/18
BOFA
02/22/18
NO CHANGE
BOFA
Buy
Shire post results weakness overdone, says BofA/Merrill
BofA/Merrill analyst Graham Parry believes Shire post results weakness is overdone and says shares remain undervalued. The analyst argued that cons EPS cuts are already priced in, and reiterates a Buy rating on the shares.
03/07/18
HCWC
03/07/18
NO CHANGE
Target $12
HCWC
Buy
Caladrius price target raised to $12 from $7 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Caladrius Biosciences (CLBS) to $12 after the company acquired from Shire (SHPG) an exclusive worldwide license to data and regulatory filings for a late-stage CD34+ cell therapy program for the treatment of chronic myocardial ischemia targeting refractory angina. The deal "significantly enriches" Caladrius' existing pipeline and should provide an "additional attractive shot on goal" in the coming years, Selvaraju tells investors in a research note. He increased his valuation of the company to $120M from $60M and reiterates a Buy rating on the shares.
03/28/18
BOFA
03/28/18
NO CHANGE
BOFA
Buy
Still considerable value in Shire even in no Takeda bid scenario, says BofA/Merrill
BofA/Merrill analyst Graham Parry notes that Takeda (TKPYY) has said in a statement that it is considering an approach for Shire (SHPG) but that the consideration is at a preliminary and exploratory stage and no approach has been made to the board of Shire. The analyst continues to see considerable value in Shire with concerns over hemophilia more than priced into the stock and upsides from pipeline, notably SHP643 for HAE and SHP647 for Ulcerative colitis and Crohns, and the value of its plasma/immunology franchise overlooked. Even in a no bid scenario, Parry believes passage through hemophilia overhangs and increased awareness of the value in these assets should see Shire trade higher on 12-month view. He reiterates a Buy rating on Shire's shares.
03/29/18
JEFF
03/29/18
NO CHANGE
Target $172
JEFF
Buy
Shire investors may be amenable to $50B-plus bid, says Jefferies
With challenges in the hemophilia market near term, Shire (SHPG) investors could be amenable to another $50B-plus bid, similar to AbbVie's (ABBV) 2014 offer, Jefferies analyst David Steinberg tells investors in a research note. This would represent a 35% premium to Shire's recent near five-year low valuation, the analyst writes. He says "it remains to be seen" how Takeda Pharmaceutical (TKPYY) could structure a transaction for Shire given the companies' similar equity valuations. The analyst finds it possible that Takeda's disclosed interest could spark competitive bids from large cap pharma companies. He keeps a Buy rating on Shire with a $172 price target.
TKPYY Takeda Pharmaceutical
$0.00

(0.00%)

10/03/17
JMPS
10/03/17
NO CHANGE
Target $25
JMPS
Outperform
Myovant Phase 3 results further de-risk ongoing trials, says JMP Securities
After Myovant Sciences (MYOV) and partner Takeda (TKPYY) announced a Japanese study evaluating the efficacy and safety of relugolix to treat uterine fibroids met its primary endpoint, JMP Securities analyst Jason Butler said the results represent a "best case outcome" and have a clear positive read through to ongoing international Phase 3 trials in uterine fibroids and endometriosis. The analyst, who increased his view of the probability of success in UF and EM, raised his price target on Myovant shares to $25 from $23 and keeps an Outperform rating on the stock.
01/16/18
BTIG
01/16/18
DOWNGRADE
BTIG
Neutral
TiGenix downgraded at BTIG to Neutral on valuation
As noted earlier, BTIG analyst Timothy Chiang downgraded TiGenix (TIG) to Neutral from Buy, saying the run-up of 81% year to date in the stock price has exceeded his target and warrants a move to the sidelines. Chiang believes that the acquisition offer by Takeda (TKPYY) will pass the required regulatory review of TiGenix lead product Alofisei in the E.U., adding that there is now less than 5% difference in the stock price relative to the Takeda offer.

TODAY'S FREE FLY STORIES

BABA

Alibaba

$162.49

5.85 (3.73%)

14:13
09/19/18
09/19
14:13
09/19/18
14:13
Periodicals
Alibaba no longer plans to bring 1M jobs to U.S. in wake of trade war, CNBC says »

Alibaba founder and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

SAFM

Sanderson Farms

$100.90

-2.04 (-1.98%)

14:09
09/19/18
09/19
14:09
09/19/18
14:09
Hot Stocks
Sanderson Farms reports on impact to operations from Hurricane Florence »

Sanderson Farms reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Oct

  • 06

    Nov

14:08
09/19/18
09/19
14:08
09/19/18
14:08
Conference/Events
RBC Capital internet analyst to hold a luncheon »

Internet Analyst Mahaney…

14:06
09/19/18
09/19
14:06
09/19/18
14:06
Conference/Events
RBC Capital multi-industry analyst to hold group luncheon »

Multi-Industry Analyst…

14:04
09/19/18
09/19
14:04
09/19/18
14:04
Conference/Events
RBC Capital biotech analysts to hold a group breakfast »

Biotech Gene Therapy…

CZR

Caesars

$10.90

0.1 (0.93%)

14:00
09/19/18
09/19
14:00
09/19/18
14:00
Options
Caesars option volume is 2X daily average and calls lead puts 10:1 »

Caesars option volume is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ELAN

Elanco

$0.00

(0.00%)

, LLY

Eli Lilly

$105.83

-1.06 (-0.99%)

13:51
09/19/18
09/19
13:51
09/19/18
13:51
Initiation
Elanco, Eli Lilly initiated  »

Elanco initiated with a…

ELAN

Elanco

$0.00

(0.00%)

LLY

Eli Lilly

$105.83

-1.06 (-0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 01

    Oct

  • 04

    Oct

  • 20

    Sep

LFUS

Littelfuse

$204.06

-9.68 (-4.53%)

13:41
09/19/18
09/19
13:41
09/19/18
13:41
Recommendations
Littelfuse analyst commentary  »

Use weakness to buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Sep

MRK

Merck

$70.16

-0.26 (-0.37%)

, BMY

Bristol-Myers

$60.93

-0.55 (-0.89%)

13:36
09/19/18
09/19
13:36
09/19/18
13:36
Periodicals
Merck cuts key cancer drug price for China launch, Caixin reports »

Merck (MRK) will cut the…

MRK

Merck

$70.16

-0.26 (-0.37%)

BMY

Bristol-Myers

$60.93

-0.55 (-0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

GLUU

Glu Mobile

$7.30

-0.285 (-3.76%)

13:35
09/19/18
09/19
13:35
09/19/18
13:35
Options
Glu Mobile put volume heavy and directionally bearish »

Bearish flow noted in Glu…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REV

Revlon

$23.75

0.5 (2.15%)

, TLRY

Tilray

$227.50

72.51 (46.78%)

13:34
09/19/18
09/19
13:34
09/19/18
13:34
Periodicals
Revlon could be set for short squeeze similar to Tilray's, Mox Reports says »

Mox Reports, which has…

REV

Revlon

$23.75

0.5 (2.15%)

TLRY

Tilray

$227.50

72.51 (46.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTWO

Take-Two

$129.93

-2.76 (-2.08%)

, SNE

Sony

$59.02

-0.8 (-1.34%)

13:32
09/19/18
09/19
13:32
09/19/18
13:32
Hot Stocks
Take-Two's Rockstar announces 'Red Dead Online' »

Take-Two's (TTWO)…

TTWO

Take-Two

$129.93

-2.76 (-2.08%)

SNE

Sony

$59.02

-0.8 (-1.34%)

MSFT

Microsoft

$111.22

-2.02 (-1.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 21

    Oct

  • 28

    Oct

  • 28

    Nov

  • 03

    Mar

13:30
09/19/18
09/19
13:30
09/19/18
13:30
General news
Hurricane Florence »

Hurricane Florence has…

13:30
09/19/18
09/19
13:30
09/19/18
13:30
General news
U.S. equities remain mixed with the Dow up »

U.S. equities remain…

AMZN

Amazon.com

$1,913.86

-27.34 (-1.41%)

13:29
09/19/18
09/19
13:29
09/19/18
13:29
Technical Analysis
Technical Take: Amazon.com attempting to bounce off third support test »

The shares are down over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEAR

Turtle Beach

$19.61

1.86 (10.48%)

13:25
09/19/18
09/19
13:25
09/19/18
13:25
Options
Turtle Beach call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WCN

Waste Connections

$79.49

-0.695 (-0.87%)

13:25
09/19/18
09/19
13:25
09/19/18
13:25
Conference/Events
Waste Connections participates in a conference call with UBS »

Analyst Windham holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
09/19/18
09/19
13:17
09/19/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
09/19/18
09/19
13:16
09/19/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRI

Darden

$117.54

-1.39 (-1.17%)

13:10
09/19/18
09/19
13:10
09/19/18
13:10
Options
Darden Restaurants with a bullish option play ahead of earnings »

Darden Restaurants with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 20

    Sep

  • 11

    Oct

SSNLF

Samsung

$0.00

(0.00%)

13:09
09/19/18
09/19
13:09
09/19/18
13:09
Periodicals
Samsung may be working on 5G variant of Galaxy 10, XDA-Developers says »

Samsung may be planning…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDXG

MiMedx

$5.39

0.11 (2.08%)

13:05
09/19/18
09/19
13:05
09/19/18
13:05
Options
MiMedx call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

AMZN

Amazon.com

$1,908.70

-32.5 (-1.67%)

, SFIX

Stitch Fix

$45.19

-5.295 (-10.49%)

12:55
09/19/18
09/19
12:55
09/19/18
12:55
Hot Stocks
Online retailers slide as Amazon reportedly testing recommendation service »

Shares of several…

AMZN

Amazon.com

$1,908.70

-32.5 (-1.67%)

SFIX

Stitch Fix

$45.19

-5.295 (-10.49%)

WMT

Walmart

$95.58

0.15 (0.16%)

FB

Facebook

$161.05

0.74 (0.46%)

W

Wayfair

$136.31

-6.92 (-4.83%)

WSM

Williams-Sonoma

$66.04

-1.3 (-1.93%)

SHOO

Steven Madden

$57.00

-0.7 (-1.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 01

    Oct

  • 28

    Oct

  • 15

    Nov

  • 03

    Mar

W

Wayfair

$136.17

-7.06 (-4.93%)

12:50
09/19/18
09/19
12:50
09/19/18
12:50
Options
Unfortunate timing for bullish ratio spread in Wayfair »

Unfortunate timing for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 03

    Mar

12:50
09/19/18
09/19
12:50
09/19/18
12:50
General news
Today's U.S. reports »

Today's U.S. reports…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.